

Acknowledgement

First and above all, I praise **ALLAH**, the almighty, the most merciful and most compassionate for providing me this opportunity and granting me the capability and endurance to proceed successfully and accomplish this work.

I would like to offer my sincerest gratitude to my supervisor **Prof. Dr. Amel Foad Ketat**, Professor of Medical Biochemistry, Faculty of Medicine, University of Alexandria for her effective help. She supported me throughout my thesis with her guidance, great experience and knowledge. One simply could not wish for a better or friendlier supervisor.

My endless thanks and gratitude to **Prof. Dr. Fairouz El Sayed Mohamed Ali**, Professor of Medical Biochemistry, Faculty of Medicine, University of Alexandria for giving me the honor to work under her supervision. She sacrificed a great deal of her valuable time to guide me throughout the work. I attribute the accomplishment of this work to her warm encouragement, thoughtful guidance, and constructive criticism.

I am greatly indebted to **Prof. Dr. Nahla Abdel Moneim Hamed**, Professor of Internal Medicine, Faculty of Medicine, University of Alexandria for offering me much advice, information and sincere help through her immense knowledge in the field of hematological diseases, and for taking time out from her busy schedule to read the manuscript. It has been a privilege working under her supervision.

I would like to take this opportunity to express my profound gratitude and appreciation to **Dr. Hazem Farag Manna**, lecturer of Medical Biochemistry, Faculty of Medicine, University of Alexandria for his kind supervision, enthusiasm and his unlimited willingness to help and give his best suggestions in every part in this work.

In my daily work I have been blessed with a friendly and cheerful group of dear professors and fellow colleagues, in many ways I have learnt much from and because of them. Many thanks are to all members of the **Medical Biochemistry Department, Faculty of Medicine, University of Alexandria** for providing a great working environment, all the support and equipment I needed to produce and complete my thesis.

I can't imagine my current position without the love and support of my family. I thank my parents, **Mr. Adel Khalil** and **Mrs. Laila Yassin**, for their great support by all means and their prayers throughout the work. Words fail to express my love and appreciation to my sisters, **Noorjahan, Hadeel** and **Wahy** and my brother, **Ahmed**. I doubt that I will ever be able to express my appreciation fully, but I owe them my eternal gratitude.

Two people who deserve special mention are **my beloved husband, Mohamed Kotb** and **my precious son, Ali**. They bore me, supported me, inspired me, empowered me and unconditionally loved me. No words can convey how much I love them.

Last but not least, I offer my sincere thanks to everyone who helped me in every step of this work, and to all the subjects who participated in the study. Without their assistance, this thesis could have never been in the current form.

LIST OF CONTENTS

Chapter	Page
ACKNOWLEDGMENT	i
LIST OF CONTENTS	ii
LIST OF TABLES	iii
LIST OF FIGURES	iv
LIST OF ABBREVIATIONS	v
I. INTRODUCTION	1
II. AIM OF THE WORK	20
III. SUBJECTS	21
IV. METHODS	22
V. RESULTS	29
VI. DISCUSSION	44
VII. SUMMARY	50
VIII. CONCLUSION	52
IX. RECOMMENDATIONS	53
X. REFERENCES	54
PROTOCOL	
APPENDIX	
ARABIC SUMMARY	

LIST OF TABLES

Table		Page
1.	Prognostic scoring systems of chronic myeloid leukemia.	6
2.	MicroRNAs Aberrantly Expressed in Cancer.	15
3.	Micro-ribonucleic acid 451 as a diagnostic biomarker of human cancer.	18
4.	Table for reverse transcription master mix preparation	25
5.	Table for reverse transcription program.	25
6.	Table for polymerase chain reaction master mix preparation.	26
7.	Table for polymerase chain reaction program.	27
8.	Comparison between the studied groups according to demographic data.	29
9.	Comparison between the studied groups according to complete blood count.	31
10.	Comparison between CML cases according to Sokal score	32
11.	Comparison between the studied groups according to BCR-ABL% at diagnosis and BCR-ABL% after treatment.	33
12.	Comparison between the studied groups according to miR-451 level.	34
13.	Comparison between the studied groups according to miR-451 expression.	36
14.	Relation between gender and miR-451 level in the studied groups.	36
15.	Relation between age and miR-451 level in the studied groups.	37
16.	Relation between Sokal score and miR-451 in in CML cases.	37
17.	Relation between miR-451 expression with BCR-ABL% at diagnosis and follow up in groups (I,II,III)	38
18.	Correlation between miR-451 with age, CBC and BCR-ABL	40
19.	Agreement (sensitivity, specificity and accuracy) for miR-451 BCR-ABL% follow up in cases group (I+II+III) (n = 45).	42

LIST OF FIGURES

Figure		Page
1.	The Philadelphia chromosome (Ph).	2
2.	Functional Domains of BCR–ABL.	3
3.	Signaling Pathways of p210 BCR–ABL.	4
4.	Chemical structures of imatinib mesylate and second generation tyrosine kinase inhibitors	7
5.	Model of micro-ribonucleic acid biogenesis.	10
6.	Ribonucleic acid-induced silencing complex (RISC) Assembly and Function	12
7.	Functions of micro-ribonucleic acid in cancer development and progression.	14
8.	Micro-ribonucleic acid 451 gene locus in human genome and the non-canonical biogenesis pathway.	17
9.	Micro-ribonucleic acid 451 as a diagnostic biomarker of human cancer.	21
10.	Applied Biosystems StepOne™ Real-Time PCR System.	26
11.	Comparison between the studied groups according to gender.	30
12.	Comparison between the studied groups according to age.	30
13.	miR-451 in the studied groups.	35
14.	Relation between miR-451 expression with BCR-ABL% at diagnosis and follow up in groups (I,II,III)	39
15.	Correlation between miR-451 with BCR-ABL% diagnosis in group I.	41
16.	Correlation between miR-451 with BCR-ABL% follow up in group I.	41
17.	ROC curve for miR-451 and BCR-ABL% follow up in cases group (I+II+III) (n = 45)	42
18.	Amplification plot of miR-451 and miR-30c.	43

LIST OF ABBREVIATIONS

3' UTR	: 3' untranslated region.
ABC	: ATP binding cassette.
ABL	: Abelson murine leukemia gene.
AGO2	: Argonaute 2 protein.
AKT	: Protein kinase B
ALT	: Alanine aminotransferase.
AP-CML	: Accelerated phase chronic myeloid leukemia.
AST	: Aspartate aminotransferase.
BCR	: Breakpoint cluster region gene.
BP-CML	: Blast crisis chronic myeloid leukemia.
C. elegans	: <i>Caenorhabditis elegans</i> .
CBC	: Complete blood count.
CBL	: Casitas B-lineage lymphoma protein.
CCyR	: Complete cytogenetic response.
CLL	: Chronic lymphocytic leukemia.
CML	: Chronic myeloid leukemia.
c-Myc	: Cyto- Myelocytomatosis.
CP-CML	: Chronic phase chronic myeloid leukemia.
CRKL	: CRK-oncogene-like protein.
CSCs	: Cancer stem cells.
C-terminal	: Carboxyl-terminal amino acid.
DBL	: Diffuse B-cell lymphoma oncogene.
DGCR8	: DiGeorge Syndrome Critical Region 8.
EDTA	: Ethylenediamine tetra-acetic acid.
FAK	: Focal adhesion kinase.
FDA	: Food and Drug Administration.
FISH	: Fluorescent in situ hybridization.

GAP	: Guanosine triphosphatase activating protein.
GDP	: Guanosine diphosphate.
GEF	: GDP–GTP exchange factor.
GRB2	: Growth factor receptor–bound protein 2.
GTP	: Guanosine triphosphate.
IM	: Imatinib mesylate.
IRIS	: International Randomized Study of Interferon Vs STI571.
JAK–STAT	: Janus kinase– signal transducers and activators of transcription.
JNK	: JUN kinase.
kDa	: Kilo daltons.
MAP kinase	: Mitogen activated pathway.
MAPKs	: Mitogen-activated protein kinases.
MDR	: Multidrug resistance
MDR1	: Multidrug resistance protein 1
miRNA, miR	: Micro-ribonucleic acid.
miRNP	: MicroRNA ribonucleoprotein complex.
MMR	: Major molecular response.
mRNA	: Messenger RNA.
mTOR	: Mammalian target of rapamycin.
NCCN	: National Comprehensive Cancer Network.
NSCLC	: Non-small cell lung cancer.
nt	: Nucleotides.
N-terminal	: amino-terminal amino acid.
PBMCs	: Peripheral blood mononuclear cells.
PCR	: Polymerase chain reaction.
P-gp	: Permeability glycoprotein
Ph	: Philadelphia chromosome.
PI3K	: Phosphatidylinositol-3-kinase.

PKB	: Protein kinase B.
Pre-miRNA	: Precursor miRNA.
pri-miRNA	: Primary miRNA.
RAB14	: Ras-related protein 14.
RAC	: RAS-like GTPase..
Ran	: RAs-related Nuclear protein.
RAS	: Guanosine triphosphate binding protein.
RISC	: RNA-induced silencing complex.
RNA pol II	: RNA polymerase II.
RNAs	: Ribonucleic acids.
RNase III	: Ribonuclease III.
SAPK	: Stress-activated protein kinase.
SEER	: Surveillance, Epidemiology, and End Results
Ser–thr	: Serine–threonine.
SH	: Sarcoma homology.
SH2	: Sarcoma (SRC) homology domain 2.
SH3	: Sarcoma (SRC) homology domain 3.
SHC	: SRC homology 2 containing protein.
SOS	: Son-of-sevenless.
TKIs	: Tyrosine-kinase inhibitors.
WHO	: World health organization.
XPO5	: Exportin-5